NHS Dudley Health Economy Medicines Formulary
Home > 5 Infections > 5.3 Antiviral drugs > 5.3.3 Viral hepatitis > 5.3.3.2 Chronic hepatitis C > Ledipasvir–sofosbuvir for treating chronic hepatitis C - NICE TAG TA363

Ledipasvir–sofosbuvir for treating chronic hepatitis C - NICE TAG TA363

1.1Ledipasvir–sofosbuvir is recommended as an option for treating chronic hepatitis C in adults, as specified in table 1.

Table 1 Ledipasvir–sofosbuvir for treating adults with chronic hepatitis C

HCV genotype, liver disease stage

Duration (weeks)

Recommendation according to treatment history

Untreated

Treated

Ledipasvir–sofosbuvir

1, without cirrhosis

8

Recommended

Not the licensed regimen for this population

12

Not recommended

Recommended

24

Not the licensed regimen for this population

Not recommended

1, with compensated cirrhosis

12

Recommended

Recommended only if all the following criteria are met:

  • Child–Pugh class A

  • platelet count of 75,000/mm3 or more

  • no features of portal hypertension

  • no history of an HCV‑associated decompensation episode

  • not previously treated with an NS5A inhibitor.

24

Not recommended

Not recommended

4, without cirrhosis

12

Not recommended

Recommended

24

Not the licensed regimen for this population

Not recommended

4, with compensated cirrhosis

12

Recommended

Recommended only if all the following criteria are met:

  • Child–Pugh class A

  • platelet count of 75,000/mm3 or more

  • no features of portal hypertension

  • no history of an HCV‑associated decompensation episode

  • not previously treated with an NS5A inhibitor.

24

Not recommended

Not recommended

Ledipasvir–sofosbuvir plus ribavirin

1

Not the licensed regimen for this population

3

24

Not recommended

4

Not the licensed regimen for this population

Abbreviation: HCV, hepatitis C virus.

Treated – the person's hepatitis C has not adequately responded to interferon‑based treatment.

1.2 It is recommended that the decision to treat and prescribing decisions are made by multidisciplinary teams in the operational delivery networks put in place by NHS England, to prioritise treatment for people with the highest unmet clinical need.

1.3 People whose treatment with ledipasvir–sofosbuvir is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/ta363

Site by Devopa
© Copyright 2019 NHS. All rights reserved.